Sumitomo Pharma Co Ltd - Company Profile
Powered by 
All the data and insights you need on Sumitomo Pharma Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Sumitomo Pharma Co Ltd Strategy Report
- Understand Sumitomo Pharma Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sumitomo Pharma Co Ltd (Sumitomo Pharma), formerly Sumitomo Dainippon Pharma Co Ltd, develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. The company offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Pharma has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Chuo-ku, Osaka, Japan.
Headquarters
Japan
Address
2-6-8, Dosho-Machi, Chuo-Ku, Osaka-Shi, 541-0045
Website
www.sumitomo-pharma.co.jp
Telephone
81 6 62035321
No of Employees
6,250
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4506 (TYO)
Revenue (2023)
$4.1B
-0.8%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-232.1%
(2023 vs 2022)
Market Cap*
$1.2B
Net Profit Margin (2023)
XYZ
-233.2%
(2023 vs 2022)
* As of and is in US$
Sumitomo Pharma Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pharmaceuticals: | Gemtesa |
| Oncology Drugs | Latuda |
| Psychiatry and Neurology Drugs | Equa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into a research collaboration with Salipro Biotech to reveal the mechanism of action and pharmacological characterization of a drug candidate. |
| 2023 | Plans/Strategy | In September, the company announced its plans to change the name of Myovant Sciences GmbH to Sumitomo Pharma Switzerland GmbH. |
| 2023 | Commercial Operation | In July, Sumitomo Pharma America, Inc launched its operations in the US and related markets. |
Competitor Comparison
| Key Parameters | Sumitomo Pharma Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka-Shi | Chuo-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku |
| State/Province | Osaka | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 6,250 | 49,095 | 14,484 | 17,435 | 7,771 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Masayo Tada | Chairman | Executive Board | - | - |
| Hiroshi Nomura | Chief Executive Officer; Director; President | Executive Board | 2018 | - |
| Toru Kimura | Executive Vice President; Chief Scientific Officer - Regenerative & Cellular Medicine Office; Regenerative and Cellular Medicine Kobe Center; Regenerative and Cellular Medicine Manufacturing Plant; Director | Executive Board | 2021 | - |
| Hitoshi Odagiri | Executive Director- Sales and Marketing Division; Head- Japan Business Unit; Director; Executive Vice President - Sales and Marketing Division; Senior Director- CNS Sales Department | Executive Board | 2018 | - |
| Yoshiharu Ikeda | Head-Japan Business Unit; Director; Senior Executive Officer-Drug Research Division | Executive Board | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward